Skip to Main Content

An official website of the United States government

Two susceptibility loci identified for prostate cancer aggressiveness.

About this Publication
Title
Two susceptibility loci identified for prostate cancer aggressiveness.
Pubmed ID
25939597 (View this publication on the PubMed website)
Publication
Nat Commun. 2015 May; Volume 6: Pages 6889
Authors
Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Grönberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, ...show more Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindström S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkund F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H, African Ancestry Prostate Cancer GWAS Consortium, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ
Affiliations
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
  • 1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA [2] Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
  • Division of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.
  • Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • CeRePP, Assistance Publique-Hôpitaux de Paris, UPMC University Paris 6, Paris, France.
  • Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Epidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303, USA.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 17177, Sweden.
  • Department of Preventative Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
  • Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
...show more
  • Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
  • Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
  • Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii 96813, USA.
  • National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London SW7 2AZ, UK.
  • Department of Genomics of Common Disease, School of Public Health, Imperial College London, London SW7 2AZ, UK.
  • 1] Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA [2] Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA.
  • Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
  • Department of Chronic Disease Prevention, National Institute for Health and Welfare, FI-00271 Helsinki, Finland.
  • Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
  • Information Management Services Inc., Rockville, Maryland 20852, USA.
Abstract

Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.

Related CDAS Studies
Related CDAS Projects